Skip to main navigation

Phio Pharmaceuticals

Home
Company
Focus
Technology
- RNAi mechanism
- Self-delivering RNAi
Investors

Home
Company
Focus
Technology
- RNAi mechanism
- Self-delivering RNAi
Investors

Investor Relations

News Releases

News Releases

December 18, 2018

Phio Pharmaceuticals to Present at Biotech Showcase™ 2019 in San Francisco

Additional Formats

PDF Version

December 4, 2018

Phio Pharmaceuticals to Present at the Tumor Targeted Lymphocytes Summit in Boston on December 13

Additional Formats

PDF Version

November 19, 2018

RXi Pharmaceuticals Corporation Changes Name to Phio Pharmaceuticals Corp.

Additional Formats

PDF Version

November 14, 2018

RXi Pharmaceuticals Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights

Additional Formats

PDF Version

November 7, 2018

RXi Pharmaceuticals to Present New Data Demonstrating the Ability of sd-rxRNA to Enhance NK Cell Activity for Adoptive Cell Transfer at SITC 2018

Additional Formats

PDF Version

November 6, 2018

RXi Pharmaceuticals to Webcast Third Quarter 2018 Financial Results on Wednesday, November 14, 2018

Additional Formats

PDF Version

October 3, 2018

RXi Pharmaceuticals Announces Closing Of $15 Million Underwritten Public Offering

Additional Formats

PDF Version

October 1, 2018

RXi Pharmaceuticals Announces Pricing Of $15 Million Upsized Underwritten Public Offering

Additional Formats

PDF Version

September 26, 2018

RXi Pharmaceuticals to Present New Data from its Immuno-Oncology Program Using sd-rxRNA Therapeutic Compounds Targeting Intracellular Checkpoint Cbl-b in NK Cells at the 16th Annual Discovery on Target Conference

Additional Formats

PDF Version

August 28, 2018

RXi Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

Additional Formats

PDF Version

August 15, 2018

RXi Pharmaceuticals and Karolinska Institutet Enter into Collaboration to Develop sd-rxRNA Compounds to Improve Functionality and Persistence of T Cells and NK Cells for the Advancement of Immuno-Oncology Therapeutics for Solid Tumors

Additional Formats

PDF Version

August 14, 2018

RXi Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights

Additional Formats

PDF Version

August 7, 2018

RXi Pharmaceuticals to Webcast Second Quarter 2018 Financial Results on Tuesday, August 14, 2018

Additional Formats

PDF Version

August 2, 2018

RXi Pharmaceuticals Granted Patents for sd-rxRNA Technology Strengthening Intellectual Property Estate in Europe and Japan

Additional Formats

PDF Version

August 1, 2018

RXi Pharmaceuticals Announces Positive Results From Phase 1/2 Trial With RXI-109 For Retinal Scarring

Additional Formats

PDF Version

June 28, 2018

BioAxone BioSciences Awarded $1.1 Million Phase 2 SBIR Funding for Continued Development of sd-rxRNA Drug Candidate for the Treatment of Spinal Cord Injury

Additional Formats

PDF Version

May 18, 2018

RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with Samcyprone™ for the Treatment of Common Warts

Additional Formats

PDF Version

May 11, 2018

RXi Pharmaceuticals Enters into Material Transfer Agreement with Iovance Biotherapeutics to Study its Self-Delivering RNAi Technology for the Advancement of Immuno-Oncology Therapeutics with Iovance's Tumor Infiltrating Lymphocytes (TILs) for Solid Tumors

Additional Formats

PDF Version

May 10, 2018

RXi Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Corporate Highlights

Additional Formats

PDF Version

May 8, 2018

RXi Pharmaceuticals Bolsters Strength of Dermatology Intellectual Property Estate Following Granting of Patent From USPTO

Additional Formats

PDF Version

May 1, 2018

RXi Pharmaceuticals Announces Presentation at the 2018 New York Oncology Investment Conference

Additional Formats

PDF Version

April 24, 2018

RXi Pharmaceuticals to Webcast First Quarter 2018 Financial Results on Thursday, May 10, 2018

Additional Formats

PDF Version

April 16, 2018

RXi Pharmaceuticals Announces Publication in Molecular Therapy on Self-Delivering RNAi (sd-rxRNA®) Targeting PD-1 in Adoptive Cell Therapy for the Treatment of Malignant Melanoma

Additional Formats

PDF Version

April 11, 2018

RXi Pharmaceuticals Announces Closing of $4.9 Million Registered Direct Offering

Additional Formats

PDF Version

April 9, 2018

RXi Pharmaceuticals Announces $4.9 Million Registered Direct Offering Priced At-the-Market

Additional Formats

PDF Version

April 4, 2018

RXi Pharmaceuticals to Present an Update on its Clinical and Cosmetic Dermatology Programs at the International Investigative Dermatology Conference

Additional Formats

PDF Version

March 26, 2018

RXi Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Recent Corporate Highlights

Additional Formats

PDF Version

March 21, 2018

RXi Pharmaceuticals to Webcast Fourth Quarter and Year End 2017 Financial Results on Monday, March 26, 2018

Additional Formats

PDF Version

March 20, 2018

RXi Pharmaceuticals Selected to Present at the Landmark Venture Forum

Additional Formats

PDF Version

February 5, 2018

RXi Pharmaceuticals to Present at the BIO CEO and Investor Conference

Additional Formats

PDF Version

January 24, 2018

RXi Pharmaceuticals Regains Compliance with NASDAQ Listing Requirements

Additional Formats

PDF Version

Print Page
Email Page
RSS Feeds
Email Alerts
IR Contact
Share

2019 Terms | Privacy Policy